Isotopes & Radiation

Two research scientists from Japan’s Kyoto University and Kochi University of Technology visited the West Valley Demonstration Project in western New York state earlier this fall to test their novel radiation detectors, the Department of Energy’s Office of Environmental Management announced on November 19.

Oklo Inc. has that it has signed a letter of intent to acquire Atomic Alchemy Inc., a U.S.-based radioisotope production company. The two companies announced a strategic partnership earlier this year.

Workers recently completed an 18-month project replacing 11 hot cell windows at the 222-S Laboratory at the Department of Energy’s Hanford Site in Washington state. Hanford contractor Navarro-ATL manages the lab.

Key developments, emerging trends, challenges, and innovations in the field of health physics are the topic of a recently published article in Health Physics Journal. The authors of “The Future of Health Physics: Trends, Challenges, and Innovation,” Lekhnath Ghimire and Edward Waller, write that they hope to “foster dialogue and collaboration for the unpredictable yet exciting journey ahead” in health physics.

TerraPower Isotopes, a subsidiary of Bellevue, Wash.–based TerraPower, announced it is now producing actinium-225 at commercial scale, making the medical isotope available to the pharmaceutical industry through weekly production runs. As a result, TerraPower Isotopes said its actinium, after further manufacturing, is now used in multiple drug developers’ radiopharmaceuticals in human clinical trials across the globe.

Kasparov

More than 80 percent of the territory that has been surveyed around the Chernobyl nuclear power plant “can be returned to agricultural production,” said Valery Kashparov, director of the Ukrainian Institute of Agricultural Radiology (UIAR) of the National University of Life and Environmental Sciences of Ukraine.

Kashparov’s team of researchers reported in a recent article in New Scientist the results of its radiation surveys of areas around the site of the 1986 nuclear power plant accident. The group concluded that radiation measurements on much of the land are now below levels regarded as unsafe by Ukrainian regulators.

Decades of research: Kashparov, who has been with the UIAR since 1998, has spent the past 37 years conducting research related to Chernobyl, focusing on the physical-chemical and nuclear-physical properties of radioactive fallout in the area.

Kilindini Harbor in Mombasa, Kenya, is East Africa’s largest international seaport. But rapid development of the Kenyan coastal zone is changing sediment distribution and dispersal patterns in the region, and shifting sediment poses safety and efficiency risks to ships in the harbor. With help from the International Atomic Energy Agency, a team of researchers from Kenya and South Africa has deployed a unique system to measure natural radionuclides in beach and aquatic sediments and map sediment transportation in the region. The IAEA described the mission in a photo essay published August 21.

QSA Global, a provider of radioisotope products, and Niowave, a Michigan-based producer of medical radioisotopes, announced that the companies will codevelop a scalable radium purification process using Niowave’s radium-226 processing technology to meet the demand for actinium-225, an alpha-emitter used in the treatment of cancer. According to the companies, the strategic partnership marks a significant advancement in the field of radiopharmaceutical technology, enhancing the supply chain for critical radioisotopes, including Ac-225.

Niowave uses a closed-loop cycle to produce high-purity Ac-225 and other alpha emitters from Ra-226 using a superconducting electron linear accelerator. According to the company’s website, the electron beam impinges on a photon converter to irradiate the Ra-226, inducing a photon-neutron reaction to Ra-225, which decays to Ac-225.

The Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) wants to mimic and accelerate the natural half-life decay chain of alpha-emitting radioisotopes and plans to invite proposals for experimental or theoretical research tracks under Decay on Demand—a new DARPA disruptioneering opportunity. The solicitation was published in draft form on June 27.

International Atomic Energy Agency experts have confirmed that the tritium concentration in the fourth batch of treated water released from Japan’s Fukushima Daiichi nuclear power plant is far below the country’s operational limit.

Irina Popova

Particle accelerators have evolved from exotic machines probing hadron interactions to understand the fundamentals of our world to widely used instruments in research and for medical and industrial use. For research purposes, high-power machines are employed, often producing secondary particle beams through primary beam interaction with a target material involving many meters of shielding. The charged beam interacts with the surrounding structures, producing both prompt radiation and secondary radiation from activated materials. After beam termination, some parts of the facility remain radioactive and potentially can become radiation hazards over time. Radiation protection for accelerator facilities involves a range of actions for operation within safe boundaries (an accelerator safety envelope). Each facility establishes fundamental safety principles, requirements, and measures to control radiation exposure to people and the release of radioactive material in the environment.

Love

The thriving gray wolf population in the Chernobyl exclusion zone (CEZ) has been the subject of recent media interest. While some sensationalist reports have referred to “mutant wolves” with “superpowers,” other news outlets have offered more sober discussions of the science behind the story.

Cara N. Love, a biologist and postdoctoral fellow in the Department of Ecology and Evolutionary Biology at Princeton University, has been following the wolf population. Her research in the Chernobyl exclusion zone (CEZ) in Ukraine and Polesie State Radioecological Reserve in Belarus is helping biologists understand how nature adapts to chronic radiation exposure.

Framatome and Nuclearelectrica, operator of Romania’s Cernavoda nuclear power plant, announced the signing of a memorandum of understanding to explore the possibility of producing the medical isotope lutetium-177. The cooperative agreement was signed during the World Nuclear Exhibition 2023, held November 28–30 in Paris.

Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.

BWX Technologies subsidiary BWXT Medical has agreed to provide Fusion Pharmaceuticals with generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

The Department of Energy Isotope Program and QSA Global, a Burlington, Mass.–based manufacturer of sealed radioisotope sources, agreed to a joint product development project to initiate domestic production of iridium-192, which is used in industrial gamma ray radiography.

The American Nuclear Society has published the following new standard, which is available for purchase in the ANS Store:

ANSI/ANS-8.21-2023, Use of Fixed Neutron Absorbers in Nuclear Facilities Outside Reactors (revision of ANSI/ANS-8.21-1995; R2019)

A Nuclear Regulatory Commission draft regulatory guide—DG-8061, “Release of Patients Administered Radioactive Material”—proposes guidance on the release of patients after a medical procedure involving the administration of radiopharmaceuticals or the implantation of a sealed source. The guidance is intended to help licensees interpret NRC regulations designed to protect the people—family, friends, caregivers, or members of the general public—who may be in proximity to a patient who is discharged after receiving nuclear medicine treatment.

The International Atomic Energy Agency has carried out the first mission of its Disused Sealed Radioactive Sources Technical Centre peer review service, or DSRS TeC, at the Thailand Institute of Nuclear Technology (TINT) in Bangkok. Held July 18–21, the inaugural mission was supported by funds from the United States.

Crapo

Bipartisan legislation has been reintroduced in Congress to strengthen the Radiation Exposure Compensation Act (RECA), improving compensation for people who were exposed to radiation as a result of working in uranium mines or living near sites of nuclear weapons testing during the Cold War. The legislation was introduced recently in the Senate by Sens. Mike Crapo (R., Idaho) and Ben Ray Luján (D., N.M.) and in the House by Rep. Teresa Leger Fernández (D., N.M.) and Del. James Moylan (R., Guam).

Follow-up bill: Originally introduced by Crapo in 2021, S. 2798 was put forward again to follow up on the success that Crapo, Luján, and Fernández had last year in extending the RECA program into 2024. The reintroduced bill, which added Moylan as a sponsor, would extend the program further to cover more communities with former uranium workers and “downwinders” (people who were exposed to radiation because they lived downwind from weapons testing sites). While the original legislation covered people in parts of Utah, Nevada, and Arizona, the bill will now also cover those who lived in Idaho, Colorado, New Mexico, and Guam.